Table 5.
Comparison of the groups at the end of the study.
| Group | (A) | (B) | (C) | (D) |
|---|---|---|---|---|
|
| ||||
| Number of cats | 22 | 16 | 22 | 16 |
| Gender of cats (male/female) | 9/13 | 7/9 | 11/11 | 9/7 |
| Median treatment dose (mg/kg/day) | 0.02 | 0.02 | Nil | Nil |
| IRIS stage 1 (number of cats) | 3 | 2 | 2 | 1 |
| IRIS stage 2 (number of cats) | 16 | 2 | 11 | 6 |
| IRIS stage 3 (number of cats) | 2 | 0 | 6 | 1 |
| IRIS stage 4 (number of cats) | 1 | 0 | 3 | 2 |
| Median creatinine concentration [25th—75th percentile] (μmol/l) | 170 [150–220] | 150 [110–170] | 240 [160–360] | 155 [150–190] |
| Median USG | 1.018 | 1.045 | 1.015 | 1.029 |
| Median bodyweight (kg) | 4.7 | 5.0 | 3.8 | 4.6 |
| Median BCS | 5 | 5.5 | 3 | 4 |
| Median duration of therapy/follow-up (days) | 467 | 327 | 475 | 648 |